Home>  Clinical Trials in Australia 

Clinical Trials in Australia

Roche reinvests approximately 18% of total sales for all products into research and development.  This currently equates to around $4 billion per year world-wide.  Of this, 35% is dedicated to oncology research, which is roughly the proportion of Roche’s current business which comes from this field. 

Australia is recognised for its sizable contribution to enrolment to global clinical trials.  While only around 1% of the world’s population resides in Australia, we contribute around 10% of participants to Roche clinical trials world-wide.   

In recognition of this, Australia has recently been established as a global headquarters for co-ordinating Roche international clinical trials.  This is extremely exciting as it will result in an increased number of international clinical trials being placed in Australia, and will allow more Australians early access to new treatments. 

Currently in Australia, Roche supports a combination of international, and local investigator-driven trials, phases I-IV.   Click on the list below for more details of the trials being run in each disease area.

A total of 45 oncology & haematology trials currently running in Australia

• 11 trials in breast cancer

• 18 trials in haematology

• 7 trials in colorectal cancer

• 3 trials in lung cancer

• 6 trials in other tumour types

Approximately 950 Australian patients will receive access to Roche Oncology & Haematology molecules through currently active phase I - III clinical trials:

A total of 950 patients in Australia will receive access to treatment on Roche Phase I-III trials

• 430 colorectal cancer patients

• 200 breast cancer patients

• 200 lung cancer patients

• 60 renal cell carcinoma patients

• 60 pancreatic cancer patients

• 10 NHL patients

• 10 gastric cancer patients

• 10,000 (approximately) months of treatment with Roche Oncology & Haematology products will be provided to these patients

In addition, approximately 1600 patients will be provided access to treatment with Roche Oncology & Haematology medications through currently active phase IV trials, Expanded Access Programmes, and Special Access Schemes.

An additional 1600 patients will receive treatment through Phase IV programmes

• 400 patients will receive MabThera

• 410 patients will receive Avastin

• 600 patients will receive Xeloda

• 125 patients will receive Tarceva

• 40 patients will receive Herceptin

 

Click here to find out how to apply for funding for a local clinical trial.  (This link is only available to healthcare professionals.)

Click here for information about the different phases of clinical trials

Frequently asked questions about clinical trials
(from Roche international trials registry website http://www.roche-trials.com/)